Home › Compare › CBCYB vs ABBV
CBCYB yields 5.43% · ABBV yields 3.06%● Live data
📍 CBCYB pulled ahead of the other in Year 2
Combined, CBCYB + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CBCYB + ABBV for your $10,000?
Central Bancompany, Inc., a multi-bank holding company, provides community banking products and services for individuals, businesses, corporates, and governments in Missouri, Kansas, Illinois, Iowa, Oklahoma, Colorado, North Carolina, Tennessee, and Florida. The company offers checking, savings, and health savings accounts; home, student, powersport, auto, personal, equipment, real estate, line of credit, and small business association loans; and mortgage, as well as home equity, credit cards, and commercial lending. It also provides brokerage, investor, retirement, and trust and wealth management services; insurance products; annuities; and cash management and investment advisory services. In addition, the company offers payment, merchant, and investment services; equipment lease and municipal financing, and business expansion financing; and custody and trust services, as well as relationship, online, and mobile banking services. The company was founded in 1902 and is headquartered in Jefferson City, Missouri.
Full CBCYB Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.